Pfizer and BioNTech, the companies that make the other messenger-RNA vaccine in U.S. circulation, previously announced their booster appeared to protect against omicron, akin to defenses the primary vaccine series provided against the ancestral strain of the virus found in Wuhan, China.
Moderna says COVID-19 booster offers 'reassuring' protection against omicron
→
“To date, there is no evidence that an adaptation of BioNTech’s current COVID-19 vaccine against key identified emerging variants is necessary,” the company said in detailing first-quarter results.
Pfizer partner BioNTech is exploring a variant-specific vaccine strategy
→